连续九年做出行业超额！易方达杨桢霄的创新药投资秘籍……

Core Viewpoint - The article emphasizes that in the pharmaceutical industry, especially after 2020, significant breakthroughs often stem from small adjustments and persistent efforts rather than dramatic revelations, highlighting the importance of understanding "micro and critical nodes" in investment strategies [2][3]. Group 1: Investment Performance and Fund Management - The article reviews the performance of active equity funds focused on the pharmaceutical sector, particularly those managed by fund managers with a tenure starting before 2017 and maintaining over 80% allocation to the pharmaceutical industry [4]. - Among the funds analyzed, only two have shown positive returns over the past three and five years, with the best performance attributed to the fund managed by Yang Zhenshao, which has consistently outperformed the pharmaceutical index since 2017 [5][6]. - Yang Zhenshao's fund, the E Fund Healthcare Industry Mixed Fund, has achieved a return of 198.63% since its inception in August 2016, with an annualized return of 12.43% and a year-to-date return of 28.92% as of December 21, 2025 [8]. Group 2: Investment Strategy and Market Insights - Yang Zhenshao's investment strategy involves in-depth research across various sub-sectors within the pharmaceutical industry, focusing on commercial models, market conditions, catalysts, and valuations to identify underrepresented sectors [10]. - The strategy has evolved from a purely bottom-up stock selection approach to a balanced focus on both alpha and beta, particularly after 2023, allowing for more comprehensive market engagement [11][12]. - The fund manager has demonstrated a keen ability to identify and capitalize on high-potential stocks, such as Nanwei Medical and Te Bao Biological, which saw significant price increases shortly after being added to the portfolio [13][14]. Group 3: Industry Trends and Future Outlook - The article notes that the Chinese pharmaceutical industry is experiencing a transformation, with companies increasingly moving towards global competitiveness and innovation, as evidenced by the rising number of new drug approvals and international collaborations [39][40]. - Yang Zhenshao has highlighted the importance of focusing on innovative drugs and high-value medical consumables, indicating a strategic shift towards sectors that are expected to thrive in the evolving market landscape [35][36]. - The outlook for the innovative drug sector is optimistic, with expectations for continued growth and increased global market presence for Chinese pharmaceutical companies [41].